Progress in therapies for cystic fibrosis

The Lancet Respiratory Medicine

Volumn 4, Issue 8, 2016, Pages 662-674

  De Boeck, Kris ^a   Amaral, Margarida D ^b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF LISBON   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBILUSTAT; ACETYLCYSTEINE; AJULEMIC ACID; ALPHA 1 ANTITRYPSIN; AMILORIDE; AMINOGLYCOSIDE DERIVATIVE; ANTIBIOTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ATALUREN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DENUFOSOL; GLUTATHIONE; ION CHANNEL; PHENYLALANINE; RIOCIGUAT; TEZACAFTOR; VORINOSTAT; CFTR PROTEIN, HUMAN;

ADULTHOOD; CELL THERAPY; CFTR GENE; CHRONIC INFLAMMATION; CLINICAL EFFECTIVENESS; COST BENEFIT ANALYSIS; CYSTIC FIBROSIS; DEVELOPMENTAL STAGE; DISEASE EXACERBATION; EX VIVO STUDY; FOLLOW UP; GENE MUTATION; GENE THERAPY; HOMOZYGOTE; HUMAN; HYDRATION; INFECTION CONTROL; LUNG INFECTION; MOLECULAR PATHOLOGY; MORALITY; MUCOCILIARY CLEARANCE; NONHUMAN; PATIENT SAFETY; PERSONALIZED MEDICINE; PNEUMONIA; PREDICTION; PRIORITY JOURNAL; PROTEIN DEFECT; QUALITY OF LIFE; SHORT SURVEY; SURVIVAL; SYMPTOM; COMPLICATION; DRUG EFFECTS; GENETICS; MOLECULARLY TARGETED THERAPY; RESPIRATORY FAILURE; TRENDS;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENETIC THERAPY; HUMANS; MOLECULAR TARGETED THERAPY; PRECISION MEDICINE; RESPIRATORY INSUFFICIENCY;

EID: 84961933652     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(16)00023-0     Document Type: Short Survey

References (138)

1. 1 Zolin, A, McKone, EF, van Rens, J, et al. ECFS Patient Registry Annual Data Report 2010, 2014, European Cystic Fibrosis Society, Karup.
2. 2 Dodge, JA, Lewis, PA, Stanton, M, Wilsher, J, Cystic fibrosis mortality and survival in the UK: 1947–2003. Eur Respir J 29 (2007), 522–526.
3. 3 Hurley, MN, McKeever, TM, Prayle, AP, Fogarty, AW, Smyth, AR, Rate of improvement of CF life expectancy exceeds that of general population—observational death registration study. J Cyst Fibros 13 (2014), 410–415.
4. 4 Riordan, JR, CFTR function and prospects for therapy. Annu Rev Biochem 77 (2008), 701–726.
5. 5 Shamsuddin, AK, Quinton, PM, Native small airways secrete bicarbonate. Am J Respir Cell Mol Biol 50 (2014), 796–804.
6. 6 Amaral, MD, Novel personalized therapies for cystic fibrosis: treating the basic defect in all patients. J Intern Med 277 (2015), 155–166.
7. 7 Sosnay, PR, Siklosi, KR, Van Goor, F, et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet 45 (2013), 1160–1167.
8. 8 Cutting, GR, Modifier genes in Mendelian disorders: the example of cystic fibrosis. Ann N Y Acad Sci 1214 (2010), 57–69.
9. 9 Guillot, L, Beucher, J, Tabary, O, Le Rouzic, P, Clement, A, Corvol, H, Lung disease modifier genes in cystic fibrosis. Int J Biochem Cell Biol 52 (2014), 83–93.
10. 10 Corvol, H, Thompson, KE, Tabary, O, le Rouzic, P, Guillot, L, Translating the genetics of cystic fibrosis to personalized medicine. Transl Res 168 (2016), 40–49.
11. 11 Amaral, MD, Balch, WE, Hallmarks of therapeutic management of the cystic fibrosis functional landscape. J Cyst Fibros 14 (2015), 687–699.
12. 12 Schraufnagel, DE, (eds.) Breathing in America: diseases, progress, and hope, 2010, American Thoracic Society, New York, 47–56 http://www.thoracic.org/patients/patient-resources/breathing-in-america/resources/chapter-5-chronic-obstructive-pulmonary-disease.pdf (accessed Sept 29, 2015).
13. 13 Johannesson, B, Hirtz, S, Schatterny, J, Schultz, C, Mall, MA, CFTR regulates early pathogenesis of chronic obstructive lung disease in βENaC-overexpressing mice. PLoS One, 7, 2012, e44059.
14. 14 Bodas, M, Tran, I, Vij, N, Therapeutic strategies to correct proteostasis-imbalance in chronic obstructive lung diseases. Curr Mol Med 12 (2012), 807–814.
15. 15 Sandford, A, The role of CFTR mutations in asthma. Can Respir J 19 (2012), 44–45.
16. 16 Tzetis, M, Efthymiadou, A, Strofalis, S, et al. CFTR gene mutations—including three novel nucleotide substitutions—and haplotype background in patients with asthma, disseminated bronchiectasis and chronic obstructive pulmonary disease. Hum Genet 108 (2001), 216–221.
17. 17 Clunes, LA, Davies, CM, Coakley, RD, et al. Cigarette smoke exposure induces CFTR internalization and insolubility, leading to airway surface liquid dehydration. FASEB J 26 (2012), 533–545.
18. 18 Sloane, PA, Shastry, S, Wilhelm, A, et al. A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung disease. PLoS One, 7, 2012, e39809.
19. 19 Boyle, MP, De Boeck, K, A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect. Lancet Respir Med 1 (2013), 158–163.
20. 20 Ramsey, BW, Davies, J, McElvaney, NG, et al., the VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 365 (2011), 1663–1672.
21. 21 De Boeck, K, Munck, A, Walker, S, et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J Cyst Fibros 13 (2014), 674–680.
22. 22 Sawicki GS, McKone E, Pasta DJ, Wagener J, Johnson C, Konstan MW. The effect of ivacaftor on the rate of lung function decline in CF patients with G551D-CFTR mutation. 37th European Cystic Fibrosis Conference; Gothenburg, Sweden; June 11–14, 2014. WS3.1.
23. 23 Amaral, MD, Kunzelmann, K, Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis. Trends Pharmacol Sci 28 (2007), 334–341.
24. 24 Smyth, AR, Bell, SC, Bojcin, S, et al., the European Cystic Fibrosis Society. European Cystic Fibrosis Society standards of care: best practice guidelines. J Cyst Fibros 13:suppl 1 (2014), S23–S42.
25. 25 Button, B, Cai, LH, Ehre, C, et al. A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia. Science 337 (2012), 937–941.
26. 26 Elkins, MR, Robinson, M, Rose, BR, et al., the National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 354 (2006), 229–240.
27. 27 Bilton, D, Daviskas, E, Anderson, SD, et al., the B301 Investigators. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest 144 (2013), 215–225.
28. 28 Konstan, MW, Wagener, JS, Pasta, DJ, et al., the Scientific Advisory Group and Investigators and Coordinators of Epidemiologic Study of Cystic Fibrosis. Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis. Pediatr Pulmonol 46 (2011), 545–553.
29. 29 Cobos, N, Danés, I, Gartner, S, González, M, Liñán, S, Arnau, JM, DNase use in the daily care of cystic fibrosis: who benefits from it and to what extent? Results of a cohort study of 199 patients in 13 centres. DNase National Study Group. Eur J Pediatr 159 (2000), 176–181.
30. 30 Sanders, NN, Franckx, H, De Boeck, K, Haustraete, J, De Smedt, SC, Demeester, J, Role of magnesium in the failure of rhDNase therapy in patients with cystic fibrosis. Thorax 61 (2006), 962–966.
31. 31 Protalix BioTherapeutics Announces AIR DNase(TM) Data Presented at the 38th European Cystic Fibrosis Conference. Protalix Biotherapeutics. http://phx.corporate-ir.net/phoenix.zhtml?c=101161&p=irol-newsArticle&ID=2058840, June 12, 2015 (accessed Sept 29, 2015).
32. 32 Bucki, R, Cruz, K, Pogoda, K, et al. Enhancement of Pulmozyme activity in purulent sputum by combination with poly-aspartic acid or gelsolin. J Cyst Fibros 14 (2015), 587–593.
33. 33 Cantin, AM, Hartl, D, Konstan, MW, Chmiel, JF, Inflammation in cystic fibrosis lung disease: pathogenesis and therapy. J Cyst Fibros 14 (2015), 419–430.
34. 34 Cohen-Cymberknoh, M, Kerem, E, Ferkol, T, Elizur, A, Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications. Thorax 68 (2013), 1157–1162.
35. 35 Govan, JR, Deretic, V, Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 60 (1996), 539–574.
36. 36 Staudinger, BJ, Muller, JF, Halldórsson, S, et al. Conditions associated with the cystic fibrosis defect promote chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 189 (2014), 812–824.
37. 37 Konstan, MW, Döring, G, Heltshe, SL, et al., the Investigators and Coordinators of BI Trial 543.45. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. J Cyst Fibros 13 (2014), 148–155.
38. 38 Eigen, H, Rosenstein, BJ, FitzSimmons, S, Schidlow, DV, the Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. J Pediatr 126 (1995), 515–523.
39. 39 Balfour-Lynn, IM, Lees, B, Hall, P, et al., the CF WISE (Withdrawal of Inhaled Steroids Evaluation) Investigators. Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. Am J Respir Crit Care Med 173 (2006), 1356–1362.
40. 40 Döring, G, Bragonzi, A, Paroni, M, et al. BIIL 284 reduces neutrophil numbers but increases P aeruginosa bacteremia and inflammation in mouse lungs. J Cyst Fibros 13 (2014), 156–163.
41. 41 Konstan, MW, Schluchter, MD, Xue, W, Davis, PB, Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 176 (2007), 1084–1089.
42. 42 Konstan, MW, VanDevanter, DR, Rasouliyan, L, et al. the Scientific Advisory Group, the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Trends in the use of routine therapies in cystic fibrosis: 1995–2005. Pediatr Pulmonol 45 (2010), 1167–1172.
43. 43 Carlile, GW, Robert, R, Goepp, J, et al. Ibuprofen rescues mutant cystic fibrosis transmembrane conductance regulator trafficking. J Cyst Fibros 14 (2015), 16–25.
44. 44 De Boeck, K, Fajac, I, Ratjen, F, End-points and biomarkers for clinical trials in cystic fibrosis. Eur Respir Monogr 64 (2014), 104–115.
45. 45 Springman E, Grosswald R, Philpot E, et al. A phase 1 clinical study of CTX-4430 in cystic fibrosis patients. 38th European Cystic Fibrosis Conference; Brussels, Belgium; June 10–13, 2015. 126.
46. 46 Corbus Pharma. http://www.corbuspharma.com/news/press-releases/detail/199/corbus-pharmaceuticals-announces-fda-orphan-drug (accessed March 25, 2016).
47. 47 Griese, M, Latzin, P, Kappler, M, et al. alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J 29 (2007), 240–250.
48. 48 Nichols D, Donaldson SH, Dorkin H, et al. A 3 week dose escalation, randomized, double-blind, placebo-controlled trial to assess the safety, tolerability, and possible efficacy of 100 mg or 200 mg of once daily inhaled alpha-1 HC in cystic fibrosis (CF). 28th Annual North American Cystic Fibrosis Conference; Atlanta, GA, USA; Oct 9–11, 2014. 281.
49. 49 Kogan, I, Ramjeesingh, M, Li, C, et al. CFTR directly mediates nucleotide-regulated glutathione flux. EMBO J 22 (2003), 1981–1989.
50. 50 Bishop, C, Hudson, VM, Hilton, SC, Wilde, C, A pilot study of the effect of inhaled buffered reduced glutathione on the clinical status of patients with cystic fibrosis. Chest 127 (2005), 308–317.
51. 51 Hartl, D, Starosta, V, Maier, K, et al. Inhaled glutathione decreases PGE2 and increases lymphocytes in cystic fibrosis lungs. Free Radic Biol Med 39 (2005), 463–472.
52. 52 Griese, M, Kappler, M, Eismann, C, et al., the Glutathione Study Group. Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial. Am J Respir Crit Care Med 188 (2013), 83–89.
53. 53 Tirouvanziam, R, Conrad, CK, Bottiglieri, T, Herzenberg, LA, Moss, RB, Herzenberg, LA, High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci USA 103 (2006), 4628–4633.
54. 54 Conrad, C, Lymp, J, Thompson, V, et al. Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial. J Cyst Fibros 14 (2015), 219–227.
55. 55 Tiddens, HA, Bos, AC, Mouton, JW, Devadason, S, Janssens, HM, Inhaled antibiotics: dry or wet?. Eur Respir J 44 (2014), 1308–1318.
56. 56 Agent, P, Parrott, H, Inhaled therapy in cystic fibrosis: agents, devices and regimens. Breathe (Sheff) 11 (2015), 110–118.
57. 57 Waters, V, Smyth, A, Cystic fibrosis microbiology: advances in antimicrobial therapy. J Cyst Fibros 14 (2015), 551–560.
58. 58 Halwani M, Balkhy HH, Khiyami MA, Omri A. Antimicrobial activity of liposomal β-glycan against Pseudomonas aeruginosa isolated from cystic fibrosis patients. 38th European Cystic Fibrosis Conference; Brussels, Belgium; June 10–13, 2015. 130.
59. 59 Pritchard MF, Ferguson LC, Powell E, et al. OligoG fluorescent conjugation for localisation in a mucoid pseudomonal biofilm. 38th European Cystic Fibrosis Conference; Brussels, Belgium; June 10–13, 2015. 139.
60. 60 Hodges L, MacGregor G, Stevens H, et al. An open label, randomised, two-way crossover scintigraphic study to investigate lung deposition of radiolabelled alginate oligosaccharide delivered as a dry powder and as a nebulised solution in cystic fibrosis patients. 28th Annual North American Cystic Fibrosis Conference; Atlanta, GA, USA; Oct 9–11, 2014. 251.
61. 61 Pritchard, MF, Powell, LC, Menzies, GE, et al. A new class of safe oligosaccharide polymer therapy to modify the mucus barrier of chronic respiratory disease. Mol Pharm 13 (2016), 863–872.
62. 62 Devereux G, Steele S, Griffiths KJ, et al. An open label investigation of the tolerability and pharmacokinetics or oral cysteamine in adults with cystic fibrosis. 38th European Cystic Fibrosis Conference; Brussels, Belgium; June 10–13, 2015. A141.
63. 63 De Stefano, D, Villella, VR, Esposito, S, et al. Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation. Autophagy 10 (2014), 2053–2074.
64. 64 Luciani, A, Villella, VR, Esposito, S, et al. Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition. Nat Cell Biol 12 (2010), 863–875.
65. 65 Grasemann, H, Michler, E, Wallot, M, Ratjen, F, Decreased concentration of exhaled nitric oxide (NO) in patients with cystic fibrosis. Pediatr Pulmonol 24 (1997), 173–177.
66. 66 Meng, QH, Springall, DR, Bishop, AE, et al. Lack of inducible nitric oxide synthase in bronchial epithelium: a possible mechanism of susceptibility to infection in cystic fibrosis. J Pathol 184 (1998), 323–331.
67. 67 Moss, RB, Mayer-Hamblett, N, Wagener, J, et al. Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease. Pediatr Pulmonol 39 (2005), 209–218.
68. 68 Miller, CC, Hergott, CA, Rohan, M, Arsenault-Mehta, K, Döring, G, Mehta, S, Inhaled nitric oxide decreases the bacterial load in a rat model of Pseudomonas aeruginosa pneumonia. J Cyst Fibros 12 (2013), 817–820.
69. 69 Blau H, Aviram M, Mussaffi H, et al. Safety and tolerability of nitric oxide given intermittently via inhalation to subjects with cystic fibrosis in a prospective open-label phase IIa trial. 28th Annual North American Cystic Fibrosis Conference; Atlanta, GA, USA; Oct 9–11, 2014. 226.
70. 70 Grasemann, H, Tullis, E, Ratjen, F, A randomized controlled trial of inhaled L-arginine in patients with cystic fibrosis. J Cyst Fibros 12 (2013), 468–474.
71. 71 Hraiech, S, Brégeon, F, Rolain, JM, Bacteriophage-based therapy in cystic fibrosis-associated Pseudomonas aeruginosa infections: rationale and current status. Drug Des Devel Ther 9 (2015), 3653–3663.
72. 72 Sahota, JS, Smith, CM, Radhakrishnan, P, et al. Bacteriophage delivery by nebulization and efficacy against phenotypically diverse Pseudomonas aeruginosa from cystic fibrosis patients. J Aerosol Med Pulm Drug Deliv 28 (2015), 353–360.
73. 73 Coburn, B, Wang, PW, Diaz Caballero, J, et al. Lung microbiota across age and disease stage in cystic fibrosis. Sci Rep, 5, 2015, 10241.
74. 74 Cystic fibrosis mutation database statistics. http://www.genet.sickkids.on.ca/StatisticsPage.html (accessed March 25, 2016).
75. 75 De Boeck, K, Zolin, A, Cuppens, H, Olesen, HV, Viviani, L, The relative frequency of CFTR mutation classes in European patients with cystic fibrosis. J Cyst Fibros 13 (2014), 403–409.
76. 76 Welsh, MJ, Smith, AE, Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73 (1993), 1251–1254.
77. 77 Zielenski, J, Tsui, LC, Cystic fibrosis: genotypic and phenotypic variations. Annu Rev Genet 29 (1995), 777–807.
78. 78 Bell, SC, De Boeck, K, Amaral, MD, New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls. Pharmacol Ther 145 (2015), 19–34.
79. 79 Rich, DP, Anderson, MP, Gregory, RJ, et al. Expression of cystic fibrosis transmembrane conductance regulator corrects defective chloride channel regulation in cystic fibrosis airway epithelial cells. Nature 347 (1990), 358–363.
80. 80 Cheng, SH, Gregory, RJ, Marshall, J, et al. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63 (1990), 827–834.
81. 81 Dörk, T, Macek, M Jr, Mekus, F, et al. Characterization of a novel 21-kb deletion, CFTRdele2,3(21 kb), in the CFTR gene: a cystic fibrosis mutation of Slavic origin common in Central and East Europe. Hum Genet 106 (2000), 259–268.
82. 82 Moss, RB, Flume, PA, Elborn, JS, et al., the VX11-770-110 (KONDUCT) Study Group. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet Respir Med 3 (2015), 524–533.
83. 83 Wainwright, CE, Elborn, JS, Ramsey, BW, et al. the TRAFFIC Study Group, the TRANSPORT Study Group. Lumacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 373 (2015), 220–231.
84. 84 Bosch, B, De Boeck, K, Searching for a cure for cystic fibrosis. A 25-year quest in a nutshell. Eur J Pediatr 175 (2016), 1–8.
85. 85 Davies, JC, Wainwright, CE, Canny, GJ, et al., the VX08-770-103 (ENVISION) Study Group. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med 187 (2013), 1219–1225.
86. 86 Hebestreit, H, Sauer-Heilborn, A, Fischer, R, Käding, M, Mainz, JG, Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation. J Cyst Fibros 12 (2013), 599–603.
87. 87 Sawicki, GS, McKone, EF, Pasta, DJ, et al. Sustained benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data. Am J Respir Crit Care Med 192 (2015), 836–842.
88. 88 Rowe, SM, Heltshe, SL, Gonska, T, et al., the GOAL Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med 190 (2014), 175–184.
89. 89 Bellin, MD, Laguna, T, Leschyshyn, J, et al. Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study. Pediatr Diabetes 14 (2013), 417–421.
90. 90 Borowitz, D, Lubarsky, B, Wilschanski, M, et al. Nutritional status improved in cystic fibrosis patients with the G551D mutation after treatment with ivacaftor. Dig Dis Sci 61 (2016), 198–207.
91. 91 Van Goor, F, Yu, H, Burton, B, Hoffman, BJ, Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J Cyst Fibros 13 (2014), 29–36.
92. 92 Igreja, S, Clarke, LA, Botelho, HM, Marques, L, Amaral, MD, Correction of a cystic fibrosis splicing mutation by antisense oligonucleotides. Hum Mutat 37 (2016), 209–215.
93. 93 Bush, A, Simmonds, NJ, Hot off the breath: ‘I've a cost for’—the 64 million dollar question. Thorax 67 (2012), 382–384.
94. 94 Whiting, P, Al, M, Burgers, L, et al. Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis. Health Technol Assess 18 (2014), 1–106.
95. 95 Flume, PA, Liou, TG, Borowitz, DS, et al., the VX 08-770-104 Study Group. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest 142 (2012), 718–724.
96. 96 Okiyoneda, T, Veit, G, Dekkers F et al. Mechanism-based corrector combination restores ΔF508-CFTR folding and function. Nat Chem Biol 9 (2013), 444–454.
97. 97 Farinha, CM, King-Underwood, J, Sousa, M, et al. Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction. Chem Biol 20 (2013), 943–955.
98. 98 Awatade, NT, Uliyakina, I, Farinha, CM, et al. Measurements of functional responses in human primary lung cells as a basis for personalized therapy for cystic fibrosis. EBioMedicine 2 (2014), 147–153.
99. 99 PROQR THERAPEUTICS N.V. (PRQR) IPO. http://www.nasdaq.com/markets/ipos/company/proqr-therapeutics-nv-942327-76207 (accessed Sept 29, 2015).
100. 100 Kerem, E, Konstan, MW, De Boeck, K, et al., the Cystic Fibrosis Ataluren Study Group. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med 2 (2014), 539–547.
101. 101 Pezzulo, AA, Tang, XX, Hoegger, MJ, et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 487 (2012), 109–113.
102. 102 Boucher, RC, Cystic fibrosis: a disease of vulnerability to airway surface dehydration. Trends Mol Med 13 (2007), 231–240.
103. 103 Quinton, PM, Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. Lancet 372 (2008), 415–417.
104. 104 Chen, EY, Yang, N, Quinton, PM, Chin, WC, A new role for bicarbonate in mucus formation. Am J Physiol Lung Cell Mol Physiol 299 (2010), L542–L549.
105. 105 Gustafsson, JK, Ermund, A, Ambort, D, et al. Bicarbonate and functional CFTR channel are required for proper mucin secretion and link cystic fibrosis with its mucus phenotype. J Exp Med 209 (2012), 1263–1272.
106. 106 Caputo, A, Caci, E, Ferrera, L, et al. TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity. Science 322 (2008), 590–594.
107. 107 Schroeder, BC, Cheng, T, Jan, YN, Jan, LY, Expression cloning of TMEM16A as a calcium-activated chloride channel subunit. Cell 134 (2008), 1019–1029.
108. 108 Yang, YD, Cho, H, Koo, JY, et al. TMEM16A confers receptor-activated calcium-dependent chloride conductance. Nature 455 (2008), 1210–1215.
109. 109 Sondo, E, Caci, E, Galietta, LJ, The TMEM16A chloride channel as an alternative therapeutic target in cystic fibrosis. Int J Biochem Cell Biol 52 (2014), 73–76.
110. 110 Mall, MA, Galietta, LJ, Targeting ion channels in cystic fibrosis. J Cyst Fibros 14 (2015), 561–570.
111. 111 Martins, JR, Faria, D, Kongsuphol, P, Reisch, B, Schreiber, R, Kunzelmann, K, Anoctamin 6 is an essential component of the outwardly rectifying chloride channel. Proc Natl Acad Sci USA 108 (2011), 18168–18172.
112. 112 Dorfman, R, Taylor, C, Lin, F, et al., the Members of Canadian Consortium for CF Genetic Studies. Modulatory effect of the SLC9A3 gene on susceptibility to infections and pulmonary function in children with cystic fibrosis. Pediatr Pulmonol 46 (2011), 385–392.
113. 113 Sun, L, Rommens, JM, Corvol, H, et al. Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis. Nat Genet 44 (2012), 562–569.
114. 114 Blackman, SM, Commander, CW, Watson, C, et al. Genetic modifiers of cystic fibrosis-related diabetes. Diabetes 62 (2013), 3627–3635.
115. 115 Moss, RB, Pitfalls of drug development: lessons learned from trials of denufosol in cystic fibrosis. J Pediatr 162 (2013), 676–680.
116. 116 Strategic Research Centre 2. INOVCF: innovative non-CFTR approaches for cystic fibrosis therapy. London: Cystic Fibrosis Trust. http://www.cysticfibrosis.org.uk/research-care/research/about-cystic-fibrosis-research/how-we-invest-in-research/strategic-research-centres/src-2 (accessed Sept 29, 2015).
117. 117 Knowles, MR, Stutts, MJ, Spock, A, Fischer, N, Gatzy, JT, Boucher, RC, Abnormal ion permeation through cystic fibrosis respiratory epithelium. Science 221 (1983), 1067–1070.
118. 118 Mall, M, Bleich, M, Greger, R, Schreiber, R, Kunzelmann, K, The amiloride-inhibitable Na+ conductance is reduced by the cystic fibrosis transmembrane conductance regulator in normal but not in cystic fibrosis airways. J Clin Invest 102 (1998), 15–21.
119. 119 Boucher, RC, Regulation of airway surface liquid volume by human airway epithelia. Pflugers Arch 445 (2003), 495–498.
120. + absorption produces cystic fibrosis-like lung disease in mice. Nat Med 10 (2004), 487–493.
121. 121 Snouwaert, JN, Brigman, KK, Latour, AM, et al. An animal model for cystic fibrosis made by gene targeting. Science 257 (1992), 1083–1088.
122. 122 Pons, G, Marchand, MC, d'Athis, P, et al., the Amiloride-AFLM Collaborative Study Group. French multicenter randomized double-blind placebo-controlled trial on nebulized amiloride in cystic fibrosis patients. Pediatr Pulmonol 30 (2000), 25–31.
123. 123 Bennett, WD, Wu, J, Fuller, F, et al. Duration of action of hypertonic saline on mucociliary clearance in the normal lung. J Appl Physiol 118 (2015), 1483–1490.
124. 124 Almaça, J, Faria, D, Sousa, M, et al. High-content siRNA screen reveals global ENaC regulators and potential cystic fibrosis therapy targets. Cell 154 (2013), 1390–1400.
125. 125 Althaus, M, Clauss, WG, Fronius, M, Amiloride-sensitive sodium channels and pulmonary edema. Pulm Med, 2011, 2011, 830320.
126. 126 Alton, EW, Armstrong, DK, Ashby, D, et al., the UK Cystic Fibrosis Gene Therapy Consortium. Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med 3 (2015), 684–691.
127. 127 Schwank, G, Koo, BK, Sasselli, V, et al. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell 13 (2013), 653–658.
128. 128 Crane, AM, Kramer, P, Bui, JH, et al. Targeted correction and restored function of the CFTR gene in cystic fibrosis induced pluripotent stem cells. Stem Cell Rev 4 (2015), 569–577.
129. 129 Balch, WE, Morimoto, RI, Dillin, A, Kelly, JW, Adapting proteostasis for disease intervention. Science 319 (2008), 916–919.
130. 130 Hutt, DM, Herman, D, Rodrigues, AP, et al. Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol 6 (2010), 25–33.
131. 131 Goubau, C, Wilschanski, M, Skalická, V, et al. Phenotypic characterisation of patients with intermediate sweat chloride values: towards validation of the European diagnostic algorithm for cystic fibrosis. Thorax 64 (2009), 683–691.
132. 132 Noone, PG, Knowles, MR, ‘CFTR-opathies’: disease phenotypes associated with cystic fibrosis transmembrane regulator gene mutations. Respir Res 2 (2001), 328–332.
133. 133 De Boeck, K, Wilschanski, M, Castellani, C, et al., the Diagnostic Working Group. Cystic fibrosis: terminology and diagnostic algorithms. Thorax 61 (2006), 627–635.
134. 134 Hirtz, S, Gonska, T, Seydewitz, HH, et al. CFTR Cl– channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis. Gastroenterology 127 (2004), 1085–1095.
135. 135 Sousa, M, Servidoni, MF, Vinagre, AM, et al. Measurements of CFTR-mediated Cl– secretion in human rectal biopsies constitute a robust biomarker for cystic fibrosis diagnosis and prognosis. PLoS One, 7, 2012, e47708.
136. 136 Beekman, JM, Sermet-Gaudelus, I, de Boeck, K, et al. CFTR functional measurements in human models for diagnosis, prognosis and personalized therapy: report on the pre-conference meeting to the 11th ECFS Basic Science Conference, Malta, 26–29 March 2014. J Cyst Fibros 13 (2014), 363–372.
137. 137 Dekkers, JF, Wiegerinck, CL, de Jonge, HR, et al. A functional CFTR assay using primary cystic fibrosis intestinal organoids. Nat Med 19 (2013), 939–945.
138. 138 Chang, EH, Zabner, J, Precision genomic medicine in cystic fibrosis. Clin Transl Sci 8 (2015), 606–610.